Fortunately, the economics of the marketplace have driven it towards big gene-printing firms. It's cheaper to outsource to a high-capital, low-cost-operating c

Fortunately, the economics of the marketplace have driven it towards big gene-printing firms. It's cheaper to outsource to a high-capital, low-cost-operating company than it is to do in house with a low-capital, high-cost-operating approach. Thus the low end of the market pretty much died and the big guys check all orders against a slew of thou-shalt-not-print genes.